In conclusion, this research established that might act as a sponge, thereby accelerating the progression of GBM by targeting E2F5, implying that circ-FOXM1 could be used as a biomarker for GBM treatment [79] (Figure 4 and Table 2). This evidence concerns the gene FOXM1 and glioblastoma.